Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising drug combo targets recurrent gynecologic cancers

NCT ID NCT03968406

First seen Feb 22, 2026 · Last updated May 24, 2026 · Updated 12 times

Summary

This early-stage study tests a drug called talazoparib combined with radiation therapy for people whose gynecologic cancer (like ovarian, uterine, or cervical) has returned. The goal is to find the safest dose and see if the combination can shrink tumors. About 24 participants will be enrolled to help determine side effects and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM RECURRENT CERVICAL CARCINOMA RECURRENT ENDOMETRIAL CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA RECURRENT VAGINAL CARCINOMA STAGE IV CERVICAL CANCER AJCC V8 STAGE IV CERVICAL CANCER AJCC V8 STAGE IV FALLOPIAN TUBE CANCER AJCC V8 STAGE IV FALLOPIAN TUBE CANCER AJCC V8 STAGE IV OVARIAN CANCER AJCC V8 STAGE IV OVARIAN CANCER AJCC V8 STAGE IV PRIMARY PERITONEAL CANCER AJCC V8 STAGE IV PRIMARY PERITONEAL CANCER AJCC V8 STAGE IV UTERINE CORPUS CANCER AJCC V8 STAGE IV UTERINE CORPUS CANCER AJCC V8 STAGE IV VAGINAL CANCER AJCC V8 STAGE IV VAGINAL CANCER AJCC V8 STAGE IVA CERVICAL CANCER AJCC V8 STAGE IVA CERVICAL CANCER AJCC V8 STAGE IVA FALLOPIAN TUBE CANCER AJCC V8 STAGE IVA FALLOPIAN TUBE CANCER AJCC V8 STAGE IVA OVARIAN CANCER AJCC V8 STAGE IVA OVARIAN CANCER AJCC V8 STAGE IVA PRIMARY PERITONEAL CANCER AJCC V8 STAGE IVA PRIMARY PERITONEAL CANCER AJCC V8 STAGE IVA UTERINE CORPUS CANCER AJCC V8 STAGE IVA UTERINE CORPUS CANCER AJCC V8 STAGE IVA VAGINAL CANCER AJCC V8 STAGE IVA VAGINAL CANCER AJCC V8 STAGE IVB CERVICAL CANCER AJCC V8 STAGE IVB CERVICAL CANCER AJCC V8 STAGE IVB FALLOPIAN TUBE CANCER AJCC V8 STAGE IVB FALLOPIAN TUBE CANCER AJCC V8 STAGE IVB OVARIAN CANCER AJCC V8 STAGE IVB OVARIAN CANCER AJCC V8 STAGE IVB PRIMARY PERITONEAL CANCER AJCC V8 STAGE IVB PRIMARY PERITONEAL CANCER AJCC V8 STAGE IVB UTERINE CORPUS CANCER AJCC V8 STAGE IVB UTERINE CORPUS CANCER AJCC V8 STAGE IVB VAGINAL CANCER AJCC V8 STAGE IVB VAGINAL CANCER AJCC V8